Volume 16, Issue 6 (3-2018)
TB 2018, 16(6): 33-42 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Dehghani A, Naderyan Feli S, Rezaei Hachesu V, Yasini Ardekani M, Mirzaei M, Fallahzadeh H et al . Investigation of Dyslipidemia and Some of Related Factors Among Patients With Schizophrenia and Bipolar Disorder in Yazd-Iran. TB 2018; 16 (6) :33-42
URL: http://tbj.ssu.ac.ir/article-1-2417-en.html
URL: http://tbj.ssu.ac.ir/article-1-2417-en.html
Ali Dehghani 
, Shadi Naderyan Feli * , Vida Rezaei Hachesu , Mojtaba Yasini Ardekani , Masoud Mirzaei , Hossein Fallahzadeh , Hossein Nough
, Shadi Naderyan Feli * , Vida Rezaei Hachesu , Mojtaba Yasini Ardekani , Masoud Mirzaei , Hossein Fallahzadeh , Hossein Nough
Shahid Sadoughi University of Medical Sciences, Yazd, Iran , naderyan67@yahoo.com
Abstract: (3649 Views)
Introduction: Mortality rates in patients with schizophrenia and bipolar disorder are higher than the general population. Cardiovascular disease is the most important of natural cause of death in these patients. The aim of this study was to assess the prevalence of dyslipidemia and some of related factors in these patients.
Methods: We conducted an analytic cross-sectional study on 200 subjects in two groups: patients with schizophrenia and bipolar disorder. Prevalence of dyslipidemia and some of related factors were calculated separately for both groups. Descriptive statistics (mean and standard deviation) were used for describing data. To compare the averages, we used independent sample t-test. Chi-square test was used for comparing the prevalence of dyslipidemia and related factors in two groups of patients.
Results: The prevalence of dyslipidemia in patients with schizophrenia and bipolar disorder was 57% and 72%, respectively (p . Among the blood lipid abnormalities, low HDL-C was the most prevalent factor in patients with schizophrenia and bipolar disorder (54% and 61%, respectively) (p ). Among the factors associated with dyslipidemia, cigarette smoking in schizophrenic patients with prevalence of 38% and abdominal obesity with prevalence of 48% in patients with bipolar disorder were the most common.
Conclusion: The Findings of this study showed the high prevalence of dyslipidemia and its related factors among patients with schizophrenia and bipolar disorder and recalls the necessity of intervention and more attention to these patients.
Methods: We conducted an analytic cross-sectional study on 200 subjects in two groups: patients with schizophrenia and bipolar disorder. Prevalence of dyslipidemia and some of related factors were calculated separately for both groups. Descriptive statistics (mean and standard deviation) were used for describing data. To compare the averages, we used independent sample t-test. Chi-square test was used for comparing the prevalence of dyslipidemia and related factors in two groups of patients.
Results: The prevalence of dyslipidemia in patients with schizophrenia and bipolar disorder was 57% and 72%, respectively (p . Among the blood lipid abnormalities, low HDL-C was the most prevalent factor in patients with schizophrenia and bipolar disorder (54% and 61%, respectively) (p ). Among the factors associated with dyslipidemia, cigarette smoking in schizophrenic patients with prevalence of 38% and abdominal obesity with prevalence of 48% in patients with bipolar disorder were the most common.
Conclusion: The Findings of this study showed the high prevalence of dyslipidemia and its related factors among patients with schizophrenia and bipolar disorder and recalls the necessity of intervention and more attention to these patients.
Type of Study: Research |
Subject:
Special
Received: 2017/01/25 | Accepted: 2017/03/12 | Published: 2018/03/14
Received: 2017/01/25 | Accepted: 2017/03/12 | Published: 2018/03/14
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
